Abstract
The total artificial heart (TAH) is a temporary biventricular support device designed to bridge patients with severe heart failure to transplantation. Patients with significant myocardial damage such as those with postinfarction ventricular septal defect, with intractable arrhythmias, and with mechanical valves or native valvular diseases who are not candidates for ventricular assist devices (VADs) are candidates for TAH implantation. The CardioWest TAH can also provide a rescue for patients with advanced cardiogenic shock, such as following massive myocardial infarction or failing on left ventricular assist device (LVAD).
The CardioWest TAH-t is implanted orthotopically as a bridge-to-transplantation. Currently the patient must remain in the hospital because they are connected to a cumbersome, albeit mobile, console that is soon to be replaced by smaller versions that will allow hospital discharge. While awaiting a transplant, patients have the time to recover and improve their health status. Patients improve their nutritional status and recover from any multisystem organ failures they may have suffered prior to transplantation. The CardioWest TAH-t is an excellent temporary option for patients who have failed medical therapy and are not candidates for an LVAD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cooley DA, Liotta D, Hallman GL, Bloodwell RD, Leachman RD, Milam JD. First human implantation of cardiac prosthesis for staged total replacement of the heart. Trans Am Soc Artif Intern Organs. 1969;15:252–66.
Devries WC, Anderson J, Joyce L, Anderson F, Hammond EH, Jarvik RK, Kolff WJ. Clinical use of the total artificial heart. N Engl J Med. 1984;310:273–8.
Vaughn CC, Copeland JG, Cheng K, Austin J, Levinson MM. Interim heart replacement with a mechanical device: an adjunct to management of allograft rejection. J Heart Transplant. 1985;4:502–5.
Copeland JG, Levinson MM, Smith RG, Icenogle TB, Vaughn C, Cheng K, Ott R, Emery RW. The total artificial heart as a bridge to transplantation. A report of two cases. JAMA. 1986;256:2991–5.
Szefner J, Cabrol C. Control and treatment of hemostasis in patients with a total artificial heart: the experience at La Pitie. In: Piffare R, editor. Anticoagulation, hemostasis, and blood preservation in cardiovascular surgery. Philadelphia: Hanley and Belfus; 1993. p. 237–64.
Copeland JG, Smith RG, Arabia FA, Nolan PE, McClellan D, Tsau PH, Sethi GK, Bose RK, Banchy ME, Covington. Cardiac replacement with a total artificial heart as a bridge-to-transplantation. N Engl J Med. 2004;351:859–67.
Copeland JG, Smith RG, Bose RK, Tsau PH, Nolan PE, Slepian MJ. Risk factor analysis for bridge to transplantation with the CardioWest total artificial heart. Ann Thorac Surg. 2008;85:1639–44.
Copeland JG, Smith RG, Arabia FA, Nolan PE, Mehta VK, McCarthy MS, Chisholm KA. Comparison of the CardioWest total artificial heart, the Novacor left ventricular assist system and the Thoratec ventricular assist system in bridge to transplantation. Ann Thorac Surg. 2001;71(3 Suppl):S92–7.
Leprince P, Bonnet N, Rama A, Leger P, Borsier X, Levasseur JP, Szefner J, Vassier E, Pavie A, Gandjbakhch. Bridge to transplantation with the Jarvik-7 (CardioWest) total artificial heart: a single center 15-year experience. J Heart Lung Transplant. 2003;22:1296–303.
Morshuis M, Reiss N, Arsoglu L, Tenderich G, Korfer R, El-Banayosy A. Implantation of CardioWest total artificial heart for irreversible acute myocardial infarction shock. Heart Surg Forum. 2007;10:E251–6.
Copeland JG, Arabia FA, Tsau PH, McClellan D, Smith RG, Slepian MJ. Total artificial hearts: bridge to transplantation. Cardiol Clin. 2003;21:110–3.
Copeland JG, Arabia FA, Smith RG, Covington D. Synthetic membrane neo-pericardium facilitates total artificial heart explantation. J Heart Lung Transplant. 2001;20:654–6.
Leprince P, Rhamati M, Bonnet N, Bors V, Rama A, Lege P, Gandjbakhch I, Pavie A. Expanded polytetrafluoroethylene membranes become more wrap surfaces of circulatory support devices in become more undergoing bridge to heart transplantation. Eur J Cardiothorac Surg. 2001;19:302–6.
Wegner JA, DiNardo JA, Arabia FA, Copeland JG. Blood loss and transfusion requirements in patients implanted with a mechanical circulatory support device undergoing cardiac transplantation. J Heart Lung Transplant. 2000;19:504–6.
Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg. 2003;125:855–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Copeland, H., Copeland, J.G., Smith, R.G. (2013). Total Artificial Heart. In: Morgan, J., Naka, Y. (eds) Surgical Treatment for Advanced Heart Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6919-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6919-3_13
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6918-6
Online ISBN: 978-1-4614-6919-3
eBook Packages: MedicineMedicine (R0)